Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism

Name: Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism
Published: 2012
License: Public Domain

KAI Pharmaceuticals · 2012

ClinicalTrials.gov · Datasets · License: Public Domain · 2012

Open Source ↗

clinical-trial

secondary hyperparathyroidism, clinical trial, phase 2, renal dialysis, chronic kidney disease-mineral and bone disorder, parathyroid hormone, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism

Related documents